Try our beta test site

Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol (NAI007)

This study has been withdrawn prior to enrollment.
(Lack of funding)
Information provided by (Responsible Party):
Brian J Lipworth, University of Dundee Identifier:
First received: January 27, 2009
Last updated: June 11, 2012
Last verified: June 2012
The objective of this study is to compare the peak dose relative bronchoprotection offered by levosalbutamol and racemic salbutamol in mild to moderate asthmatics preselected into two groups on the basis of their beta-2 adrenoreceptor polymorphisms.

Condition Intervention Phase
Drug: levosalbutamol
Drug: racemic salbutamol
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Proof of Concept Study to Evaluate the Peak Bronchoprotection Conferred by Single and Chronic Dosing With Levosalbutamol and Racemic Salbutamol in Persistent Asthmatics.

Resource links provided by NLM:

Further study details as provided by University of Dundee:

Primary Outcome Measures:
  • Methacholine challenge [ Time Frame: Before and 30 mins after drug administration, and after 2 weeks of chronic treatment ]

Secondary Outcome Measures:
  • Salbutamol pharmacokinetics [ Time Frame: over 30 minutes after drug administration, one day 1 and 14 of a 2 week study period ]
  • Spirometry [ Time Frame: before and 30 mins after drug administration, at single dose and after 2 weeks chronic dosing ]
  • potassium [ Time Frame: before and 30 mins after drug administration, at single dose and after 2 weeks chronic dosing ]

Enrollment: 0
Study Start Date: January 2009
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1:levosalbutamol
2 puffs four times a day for 2 weeks
Drug: levosalbutamol
2 puffs four times a day for 2 weeks
Active Comparator: 2: racemic salbutamol
2 puffs four times a day for 2 weeks
Drug: racemic salbutamol
2 puffs four times a day for 2 weeks
Other Name: ventolin
Placebo Comparator: 3: Placebo
2 puffs four times a day for 2 weeks
Drug: placebo
2 puffs four times a day for 2 weeks
Other Name: placebo to salbutamol


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Mild to moderate stable asthmatics on ≤ 2000μg BDP or equivalent
  2. Methacholine responsive PC20< 4 mg/ml
  3. >1dd change in methacholine PC20 after the administration of racemic Salbutamol.
  4. Male or female 18-65
  5. Informed Consent
  6. Ability to comply with the requirements of the protocol

Exclusion Criteria:

  1. Severe asthmatics as defined by an FEV1≤ 60% or PEF variability > 30% or with continual daytime or nocturnal symptoms.
  2. The use of oral corticosteroids within the last 3 months.
  3. Recent respiratory tract infection (2 months).
  4. Significant concomitant respiratory disease such as COPD, CF, ABPA, bronchiectasis and active pulmonary tuberculosis.
  5. Any other clinically significant medical condition such as unstable angina, acute myocardial infarction in the preceding 3 months, recent TIA/ CVA,that may endanger the health or safety of the participant, or jeopardise the protocol.
  6. Any significant abnormal laboratory result as deemed by the investigators
  7. Pregnancy, planned pregnancy or lactation
  8. Known or suspected contra-indication to any of the IMP's
  9. Concomitant use of medicines (prescribed, over the counter or herbal) that may interfere with the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00830882

United Kingdom
Asthma and Allergy Research Group
Dundee, Angus, United Kingdom, DD1 9SY
Sponsors and Collaborators
University of Dundee
Principal Investigator: Karine L Clearie, MBBS, MRCP Asthma and Allergy Research Group
Study Director: Brian J Lipworth, MBchB Asthma and Allergy Research Group
  More Information

Responsible Party: Brian J Lipworth, Professor, University of Dundee Identifier: NCT00830882     History of Changes
Other Study ID Numbers: NAI007
Study First Received: January 27, 2009
Last Updated: June 11, 2012

Keywords provided by University of Dundee:

Additional relevant MeSH terms:
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on March 27, 2017